Page 1973 - Williams Hematology ( PDFDrive )

1948 Part XII: Hemostasis and Thrombosis <CN>: Molecular Biology and Biochemistry of the Coagulation Factors PB

371. Monroe DM, Hoffman M, Roberts HR: Platelets and thrombin generation. Arterioscler 387. Clark SR, Ma AC, Tavener SA, et al: Platelet TLR4 activates neutrophil extracellular
Thromb Vasc Biol 22:1381–1389, 2002. traps to ensnare bacteria in septic blood. Nat Med 13:463–469, 2007.
372. Cawthern KM, van ‘t Veer C, Lock JB, et al: Blood coagulation in hemophilia A and 388. Wang Y, Li M, Stadler S, et al: Histone hypercitrullination mediates chromatin decon-
hemophilia C. Blood 91:4581–4592, 1998. densation and neutrophil extracellular trap formation. J Cell Biol 184:205–213, 2009.
373. Monroe DM, Roberts HR, Hoffman M: Platelet procoagulant complex assembly in a 389. Semeraro F, Ammollo CT, Morrissey JH, et al: Extracellular histones promote thrombin
tissue factor-initiated system. Br J Haematol 88:364–371, 1994. generation through platelet-dependent mechanisms: Involvement of platelet TLR2 and
374. Schuijt TJ, Bakhtiari K, Daffre S, et al: Factor Xa activation of factor V is of paramount TLR4. Blood 118:1952–1961, 2011.
importance in initiating the coagulation system: Lessons from a tick salivary protein. 390. Martinod K, Demers M, Fuchs TA, et al: Neutrophil histone modification by peptidy-
Circulation 128:254–266, 2013. larginine deiminase 4 is critical for deep vein thrombosis in mice. Proc Natl Acad Sci U
375. Allen DH, Tracy PB: Human coagulation factor V is activated to the functional cofactor S A 110:8674–8679, 2013.
by elastase and cathepsin G expressed at the monocyte surface. J Biol Chem 270:1408– 391. Savchenko AS, Martinod K, Seidman MA, et al: Neutrophil extracellular traps form
1415, 1995. predominantly during the organizing stage of human venous thromboembolism devel-
376. Williamson P, Bevers EM, Smeets EF, et al: Continuous analysis of the mechanism of opment. J Thromb Haemost 12:860–870, 2014.
activated transbilayer lipid movement in platelets. Biochemistry 34:10448–10455, 1995. 392. Hanson SR, Griffin JH, Harker LA, et al: Antithrombotic effects of thrombin-induced
377. Yang X, Walsh PN: An ordered sequential mechanism for factor IX and factor IXa bind- activation of endogenous protein C in primates. J Clin Invest 92:2003–2012, 1993.
ing to platelet receptors in the assembly of the Factor X-activating complex. Biochem J 393. de Agostini AI, Watkins SC, Slayter HS, et al: Localization of anticoagulantly active
390(Pt 1):157–167, 2005. heparan sulfate proteoglycans in vascular endothelium: Antithrombin binding on cul-
378. White-Adams TC, Berny MA, Tucker EI, et al: Identification of coagulation factor XI tured endothelial cells and perfused rat aorta. J Cell Biol 111:1293–1304, 1990.
as a ligand for platelet apolipoprotein E receptor 2 (ApoER2). Arterioscler Thromb Vasc 394. Marcus AJ, Broekman MJ, Drosopoulos JH, et al: The endothelial cell ecto-ADPase
Biol 29:1602–1607, 2009. responsible for inhibition of platelet function is CD39. J Clin Invest 99:1351–1360, 1997.
379. Choi SH, Smith SA, Morrissey JH: Polyphosphate is a cofactor for the activation of 395. van ‘t Veer C, Golden NJ, Kalafatis M, Mann KG: Inhibitory mechanism of the protein
factor XI by thrombin. Blood 118:6963–6970, 2011. C pathway on tissue factor-induced thrombin generation. Synergistic effect in combi-
380. von dem Borne PA, Bajzar L, Meijers JC, et al: Thrombin-mediated activation of fac- nation with tissue factor pathway inhibitor. J Biol Chem 272:7983–7994, 1997.
tor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of 396. Jesty J, Beltrami E: Positive feedbacks of coagulation: Their role in threshold regulation.
fibrinolysis. J Clin Invest 99:2323–2327, 1997. Arterioscler Thromb Vasc Biol 25:2463–2469, 2005.
381. Mackman N: Tissue-specific hemostasis in mice. Arterioscler Thromb Vasc Biol 397. Brakman P, Albrechtsen OK, Astrup T: A comparative study of coagulation and
25:2273–2281, 2005. fibrinolysis in blood from normal men and women. Br J Haematol 12:74–85, 1966.
382. Kenne E, Renne T: Factor XII: A drug target for safe interference with thrombosis and 398. Nossel HL, Yudelman I, Canfield RE, et al: Measurement of fibrinopeptide A in human
inflammation. Drug Discov Today 19:1459–1464, 2014. blood. J Clin Invest 54:43–53, 1974.
383. Buller HR, Bethune C, Bhanot S, et al: Factor XI antisense oligonucleotide for preven- 399. Bauer KA, Kass BL, ten Cate H, et al: Detection of factor X activation in humans. Blood
tion of venous thrombosis. N Engl J Med 372:232–240, 2015. 74:2007–2015, 1989.
384. Engelmann B, Massberg S: Thrombosis as an intravascular effector of innate immunity. 400. Bauer KA, Kass BL, ten Cate H, et al: Factor IX is activated in vivo by the tissue factor
Nat Rev Immunol 13:34–45, 2013. mechanism. Blood 76:731–736, 1990.
385. von Bruhl ML, Stark K, Steinhart A, et al: Monocytes, neutrophils, and platelets cooper- 401. Morrissey JH: Tissue factor modulation of factor VIIa activity: Use in measuring trace
ate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 209:819–835, levels of factor VIIa in plasma. Thromb Haemost 74:185–188, 1995.
2012. 402. Conard J, Bauer KA, Gruber A, et al: Normalization of markers of coagulation activa-
386. Broze GJ Jr: Binding of human factor VII and VIIa to monocytes. J Clin Invest 70: tion with a purified protein C concentrate in adults with homozygous protein C defi-
526–535, 1982. ciency. Blood 82:1159–1164, 1993.

Kaushansky_chapter 113_p1915-1948.indd 1948 9/21/15 2:41 PM